Anturec Pharmaceuticals

Executive Summary

Anturec Pharmaceuticals is a German biotech startup pioneering a novel therapeutic platform that targets tumor vasculature via CD13, a receptor expressed on angiogenic blood vessels. Its lead candidate, tTF-NGR, is a fusion protein combining a truncated form of human tissue factor with a CD13-binding peptide (NGR). Upon binding to CD13 on tumor endothelial cells, tTF-NGR induces localized blood clotting, leading to tumor vascular occlusion and infarction. This unique mechanism of action offers a potentially universal approach for solid tumors, as it exploits tumor vasculature rather than tumor cells themselves, reducing the risk of resistance and broadening applicability across cancer types. Currently, tTF-NGR is in Phase III clinical development in combination with trabectedin for advanced soft tissue sarcomas. The Phase III trial represents a critical milestone, building on earlier evidence of efficacy and safety. If successful, tTF-NGR could become a cornerstone of vascular-targeted therapy, with potential expansion into other solid tumors. The company's focus on this innovative approach, combined with its advanced clinical stage, positions Anturec as a high-upside opportunity in the oncology landscape, though risks remain typical for Phase III programs.

Upcoming Catalysts (preview)

• Q4 2026Phase III top-line data for tTF-NGR + trabectedin in soft tissue sarcoma65% success
• Q2 2027Initiation of Phase II trial in additional solid tumor indication50% success